Developer docs
API playgroundTry for free, no card

Search company profiles

BiGEN

Full company profile

uuid000uswv

Namestring
BiGEN
Legal namestring
BiGEN Co., Ltd.
Websiteurl
bi-gen.com
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech investment services, cell therapy investment, gene therapy ventures, pharmaceutical formulation services, biotech venture capital
Industry2 codes
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Biotech Investment Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Equity Investment Returns
TypeLicensing Royalties
Description

BiGEN generates returns through equity investments in promising biotech companies, participating in Series A, B, and C funding rounds. Returns are realized through strategic partnerships, capital appreciation, and successful clinical development of portfolio companies.

bi-gen.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BiGEN operates as a biotech investment company that identifies and evaluates promising cell and gene therapy technologies developed by biotech companies, executes equity capital investment in qualified companies (Series A through C rounds), and establishes cooperative relationships with partner companies for further business development. In parallel, BiGEN serves as the Asian representative for ProJect Pharmaceutics GmbH, connecting Asian biopharmaceutical developers with parenteral drug formulation services spanning biopharmaceuticals, proteins, peptides, ADCs, live virus vaccines, and cytotoxics.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BiGEN is a biotech investment company that provides equity investment in promising biotech companies and strategic partnership services. The company operates through three main investment portfolio companies: Momotaro-gene (developing adenoviral vector-based gene therapy for solid cancer), JUNTEN BIO (developing cell therapy products for immunotolerance in transplant patients), and Noile-Immune Biotech (developing PRIME CAR-T technology for solid tumors). BiGEN also serves as the Asian representative for ProJect Pharmaceutics' pharmaceutical formulation services and partners with CDMO Binex for manufacturing support.

Product and service3 records
1Biotech Equity Investment Services
CategoryInvestment Services
Description

Equity capital investment services targeting early- to mid-stage biotech companies developing CAR-T cell therapies, gene therapies using adenoviral vectors, and regenerative medicine, with active participation across Series A, B, and C funding rounds. The service includes deal identification, technology evaluation, investment execution, and ongoing strategic partnership facilitation.

2Asian Representation for ProJect Pharmaceutics Pharmaceutical Formulation Services
CategoryPharmaceutical Services Representation
Description

Channel representation services connecting Asian biopharmaceutical developers with ProJect Pharmaceutics GmbH's specialized parenteral drug formulation services covering biopharmaceuticals, proteins, peptides, ADCs, live virus vaccines, cytotoxics, and small molecules, supported by scientific justification packages.

3Strategic Biotech Partnership Development
CategoryBiotech Business Development Services
Description

Strategic partnership facilitation services supporting biotech portfolio companies in establishing cooperative relationships with partner companies and international collaborators for business development across cancer treatment, autoimmune disease, and organ transplantation indications.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-04-18
Description

BiGEN acts as the Asian representative of ProJect Pharmaceutics GmbH, a pharmaceutical service provider specialized in formulation and process development for parenteral drug products. BiGEN obtained exclusive right to promote PJP's formulation service in the territory of Asia.

2Binex Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Binex is a Contract Development and Manufacturing Organization located in South Korea, providing full range services from cell line development to GMP manufacturing for drug substance and drug product. Services cover cGMP manufacturing for IMPs and commercial products.

bi-gen.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of Korea's largest VC/PE firms with a substantial healthcare/life sciences portfolio. Comparable to BiGEN in mandate (Korean equity investment in growth-stage companies) but with significantly larger AUM, broader sector coverage, and deeper resources.

TypeBroad incumbent
Description

Global healthcare-dedicated investment firm managing private equity, venture, and royalty funds across biotech and medtech. Overlaps with BiGEN in providing equity and structured capital to biotech companies but with vastly larger AUM and global reach.

3SBI Investment
TypeDirect peer
Description

Japan's largest independent venture capital firm with dedicated biotech/CGT investment programs. Competes directly with BiGEN for Japanese biotech investments such as CAR-T and gene therapy platforms, and is a likely co-investor or rival on deals like Noile-Immune Biotech.

TypeDirect peer
Description

Korean venture capital and growth investment firm with active portfolio exposure to healthcare and biotech. Competes with BiGEN in Korea for biotech deal flow and frequently co-invests in the same Series A/B rounds.

TypeDirect peer
Description

Korea-based venture capital and growth equity firm with a dedicated healthcare and biotech investment practice. Operates in the same Korean biotech VC market as BiGEN, providing equity capital, strategic support, and follow-on financing to similar-stage Korean and regional biotech companies.

TypeBroad incumbent
Description

US-based venture capital firm focused exclusively on early-stage biotech and life sciences. Comparable to BiGEN in vertical specialization (biotech-only investing) but operates at significantly larger scale across a global portfolio of next-generation therapeutics companies.

TypeDirect peer
Description

Pioneering Japanese VC firm with a long-standing healthcare and life sciences practice. Overlaps with BiGEN in targeting Japanese biotech Series A/B rounds and in providing follow-on capital and post-investment support to portfolio companies.

8JIC Capital
TypeDirect peer
Description

Japanese institutional investor focused on growth-stage companies including biotech. Comparable in Japanese market presence and growth-equity orientation to BiGEN, particularly in supporting biotech companies through late-stage financing rounds.

TypeBroad incumbent
Description

Biotech-focused venture capital firm investing across oncology, cell/gene therapy, and rare diseases. Comparable to BiGEN in pure-play biotech mandate, including exposure to CAR-T and cell therapy assets, though it operates at larger fund size and broader geographic scope.

10Mirae Asset Venture Investment
TypeDirect peer
Description

Korean venture capital arm of Mirae Asset Financial Group with active investments in biotech and healthcare. Competes with BiGEN for early-stage biotech deal flow in Korea and frequently participates in the same Korean Series A/B financings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment4 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BiGEN

Biotech Investment Servicesbi-gen.com

BiGEN firmographics

Firmographics
Name
BiGEN
Legal name
BiGEN Co., Ltd.
Website
https://bi-gen.com
Company type
Private
Founded year
2015
Operating status
Operating
Ownership category
akta.pro rank

BiGEN industry classification

Industry
Product category
Biotech Investment Services
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
SECONDARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Biotech investment services
  • Cell therapy investment
  • Gene therapy ventures
  • Pharmaceutical formulation services
  • Biotech venture capital

Where BiGEN is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

BiGEN business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Revenue model

  1. Equity Investment Returns: BiGEN generates returns through equity investments in promising biotech companies, participating in Series A, B, and C funding rounds. Returns are realized through strategic partnerships, capital appreciation, and successful clinical development of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

BiGEN product offering

Product offering

Core offering

BiGEN operates as a biotech investment company that identifies and evaluates promising cell and gene therapy technologies developed by biotech companies, executes equity capital investment in qualified companies (Series A through C rounds), and establishes cooperative relationships with partner companies for further business development. In parallel, BiGEN serves as the Asian representative for ProJect Pharmaceutics GmbH, connecting Asian biopharmaceutical developers with parenteral drug formulation services spanning biopharmaceuticals, proteins, peptides, ADCs, live virus vaccines, and cytotoxics.

Product overview

BiGEN is a biotech investment company that provides equity investment in promising biotech companies and strategic partnership services. The company operates through three main investment portfolio companies: Momotaro-gene (developing adenoviral vector-based gene therapy for solid cancer), JUNTEN BIO (developing cell therapy products for immunotolerance in transplant patients), and Noile-Immune Biotech (developing PRIME CAR-T technology for solid tumors). BiGEN also serves as the Asian representative for ProJect Pharmaceutics' pharmaceutical formulation services and partners with CDMO Binex for manufacturing support.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotech Equity Investment Services Equity capital investment services targeting early- to mid-stage biotech companies developing CAR-T cell therapies, gene therapies using adenoviral vectors, and regenerative medicine, with active participation across Series A, B, and C funding rounds. The service includes deal identification, technology evaluation, investment execution, and ongoing strategic partnership facilitation.
  • Asian Representation for ProJect Pharmaceutics Pharmaceutical Formulation Services Channel representation services connecting Asian biopharmaceutical developers with ProJect Pharmaceutics GmbH's specialized parenteral drug formulation services covering biopharmaceuticals, proteins, peptides, ADCs, live virus vaccines, cytotoxics, and small molecules, supported by scientific justification packages.
  • Strategic Biotech Partnership Development Strategic partnership facilitation services supporting biotech portfolio companies in establishing cooperative relationships with partner companies and international collaborators for business development across cancer treatment, autoimmune disease, and organ transplantation indications.

Companies that use BiGEN

Customer profile

Segments1 record

Ideal customer profiles2 records

BiGEN technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BiGEN partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ProJect Pharmaceutics GmbHcoreChannel Partner/ Reseller/ Distributor · 18 April 2018BiGEN acts as the Asian representative of ProJect Pharmaceutics GmbH, a pharmaceutical service provider specialized in formulation and process development for parenteral drug products. BiGEN obtained exclusive right to promote PJP's formulation service in the territory of Asia.
  • Binex Co., Ltd.coreStrategic or Co-development PartnerBinex is a Contract Development and Manufacturing Organization located in South Korea, providing full range services from cell line development to GMP manufacturing for drug substance and drug product. Services cover cGMP manufacturing for IMPs and commercial products.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

BiGEN competitors and assessment

Company assessment

Direct peers

  • Korea Investment Partners: One of Korea's largest VC/PE firms with a substantial healthcare/life sciences portfolio. Comparable to BiGEN in mandate (Korean equity investment in growth-stage companies) but with significantly larger AUM, broader sector coverage, and deeper resources.
  • SBI Investment: Japan's largest independent venture capital firm with dedicated biotech/CGT investment programs. Competes directly with BiGEN for Japanese biotech investments such as CAR-T and gene therapy platforms, and is a likely co-investor or rival on deals like Noile-Immune Biotech.
  • Aju IB Investment: Korean venture capital and growth investment firm with active portfolio exposure to healthcare and biotech. Competes with BiGEN in Korea for biotech deal flow and frequently co-invests in the same Series A/B rounds.
  • LB Investment: Korea-based venture capital and growth equity firm with a dedicated healthcare and biotech investment practice. Operates in the same Korean biotech VC market as BiGEN, providing equity capital, strategic support, and follow-on financing to similar-stage Korean and regional biotech companies.
  • JAFCO: Pioneering Japanese VC firm with a long-standing healthcare and life sciences practice. Overlaps with BiGEN in targeting Japanese biotech Series A/B rounds and in providing follow-on capital and post-investment support to portfolio companies.
  • JIC Capital: Japanese institutional investor focused on growth-stage companies including biotech. Comparable in Japanese market presence and growth-equity orientation to BiGEN, particularly in supporting biotech companies through late-stage financing rounds.
  • Mirae Asset Venture Investment: Korean venture capital arm of Mirae Asset Financial Group with active investments in biotech and healthcare. Competes with BiGEN for early-stage biotech deal flow in Korea and frequently participates in the same Korean Series A/B financings.

Broad incumbents

  • OrbiMed: Global healthcare-dedicated investment firm managing private equity, venture, and royalty funds across biotech and medtech. Overlaps with BiGEN in providing equity and structured capital to biotech companies but with vastly larger AUM and global reach.
  • ARCH Venture Partners: US-based venture capital firm focused exclusively on early-stage biotech and life sciences. Comparable to BiGEN in vertical specialization (biotech-only investing) but operates at significantly larger scale across a global portfolio of next-generation therapeutics companies.
  • MPM Capital: Biotech-focused venture capital firm investing across oncology, cell/gene therapy, and rare diseases. Comparable to BiGEN in pure-play biotech mandate, including exposure to CAR-T and cell therapy assets, though it operates at larger fund size and broader geographic scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

BiGEN financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BiGEN leadership team

Management profile

Number of profiles

Profiles4 records

BiGEN funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BiGEN M&A and investment

M&A and investment

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiGEN

What does BiGEN do?

BiGEN operates as a biotech investment company that identifies and evaluates promising cell and gene therapy technologies developed by biotech companies, executes equity capital investment in qualified companies (Series A through C rounds), and establishes cooperative relationships with partner companies for further business development. In parallel, BiGEN serves as the Asian representative for ProJect Pharmaceutics GmbH, connecting Asian biopharmaceutical developers with parenteral drug formulation services spanning biopharmaceuticals, proteins, peptides, ADCs, live virus vaccines, and cytotoxics.

Is BiGEN a public or private company?

BiGEN is a private company. It is classified as unknown and is currently operating.

When was BiGEN founded?

BiGEN was founded in 2015.

Where is BiGEN based?

BiGEN is headquartered in Seoul, South Korea, in the Asia region.

How does BiGEN make money?

One revenue line is on record: equity Investment Returns.

Who are BiGEN's main competitors?

Direct peers on record are Korea Investment Partners, SBI Investment, Aju IB Investment, LB Investment, JAFCO, JIC Capital and Mirae Asset Venture Investment. Broad incumbents are OrbiMed, ARCH Venture Partners and MPM Capital.

Does BiGEN have an API?

No public API is recorded for BiGEN.

What industry is BiGEN in?

BiGEN's product category is Biotech Investment Services. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales